
Biosimilars are back... Or are they?
As blockbuster drugs go off patent, the pharmaceutical industry is scrambling for fresh revenue sources. Follow-on versions of biologics, or "biosimilars," are being pitched as BigPharma's saving grace...
Khadijah M. Britton, JD, is founder of BetterBio, a Massachusetts-registered nonprofit and fiscally sponsored project of the 501(c)(3) Fractured Atlas whose mission is to empower journalism that reinforces the intimate connection between life and science. BetterBio provides a platform for comprehensive science reporting, challenging us to ask hard questions and debunk dangerous myths while addressing our collective social responsibility. Khadijah also serves as Chief Communications Officer for the Open Science Alliance and 2011 Open Science Summit. She has recently relocated to Washington, DC and is excited to be at the heart of US health and science policy. Follow Khadijah Britton on Twitter @KMBTweets
As blockbuster drugs go off patent, the pharmaceutical industry is scrambling for fresh revenue sources. Follow-on versions of biologics, or "biosimilars," are being pitched as BigPharma's saving grace...
As blockbuster drugs go off patent, the pharmaceutical industry is scrambling for fresh revenue sources. Follow-on versions of biologics, or “biosimilars,” are being pitched as BigPharma’s saving grace...
A Hard Look at Last Week's "Objective Attractiveness" Analysis in Psychology Today If what I say is wrong (because it is illogical or lacks credible scientific evidence), then it is my problem...
Support science journalism.
Thanks for reading Scientific American. Knowledge awaits.
Already a subscriber? Sign in.
Thanks for reading Scientific American. Create your free account or Sign in to continue.
Create Account